LimmaTech awarded FDA fast track designation for vaccine candidate against Staphylococcus aureus

19 December 2024 - LimmaTech Biologics announced today that the US FDA has granted fast track designation to LimmaTech’s multivalent ...

Read more →

UK MHRA grants innovation passport designation to ILiAD Biotechnologies BPZE1 next generation intranasal pertussis vaccine

4 December 2024 - ILiAD Biotechnologies today announced that the UK MHRA has granted Innovation Passport designation to BPZE1, the leading ...

Read more →

Two combination vaccine candidates for prevention of influenza and COVID-19 granted fast track designation in the US

11 December 2024 - Two Phase 1/2 clinical studies are ongoing to evaluate the safety profile and immune response induced by ...

Read more →

Moderna’s mRNA vaccines to be exempted from advisory committee scrutiny under $2 billion Morrison era deal

10 December 2024 - Critics say exemption ‘deeply concerning’ and risks creating separate assessment systems. ...

Read more →

GSK’s fully liquid Menveo meningococcal vaccine approved by European Commission

27 November 2024 - New fully liquid presentation means reconstitution is not needed before use. ...

Read more →

Valneva submits label extension application for its Chikungunya vaccine, Ixchiq, to the US FDA

26 November 2024 - To potentially include adolescents and antibody persistence up to two years. ...

Read more →

MHRA approves adapted Nuvaxovid JN.1 COVID-19 vaccine for adults and children aged 12 plus

15 November 2024 - The MHRA has approved an adapted version of the Nuvaxovid COVID-19 vaccine that targets the Omicron JN.1 ...

Read more →

How the Morrison Government passed over an Australian company for a US pharmaceutical giant

13 November 2024 - Australia’s audit office will probe the Morrison Government’s $2 billion deal with US pharmaceutical giant Moderna ...

Read more →

World leading approach to protect babies from RSV

10 November 2024 - Australian mums and their newborn babies will have free access to the best and most comprehensive ...

Read more →

Moderna receives Health Canada approval for RSV vaccine for adults aged 60 years and older

8 November 2024 - mRESVIA is Moderna's second approved product in Canada, the first mRNA vaccine against RSV, and the only ...

Read more →

Expanded age indication for GSK's Arexvy, the first respiratory syncytial virus vaccine approved in Canada for adults aged 50-59 at increased risk

5 November 2024 - Clinical development program continues to evaluate safety and immunogenicity in adults aged 18-49 at increased risk ...

Read more →

NS parents dismayed by lack of access to new RSV vaccines for infants

3 November 2024 - Officials say there is no universally available, publicly funded RSV vaccine program for newborns in Nova Scotia. ...

Read more →

US FDA approves Pfizer’s RSV vaccine Abrysvo for adults aged 18 to 59 at increased risk for disease

22 October 2024 - Approval based on data from pivotal Phase 3 trial in adults at increased risk of lower ...

Read more →

PHARMAC seeking bids from suppliers for COVID-19 vaccines

17 October 2024 - PHARMAC is seeking bids from pharmaceutical suppliers of COVID-19 vaccines. ...

Read more →

Valneva and LimmaTech awarded FDA fast track designation for tetravalent Shigella vaccine candidate S4V

16 October 2024 - Valneva and LimmaTech Biologics announced today that the US FDA has granted fast track designation to ...

Read more →